SAINT: Safe Induction of Labor Trial

Phase 3

Recruiting

• Conditions: Labor Complication; Induced; Birth; Pregnancy Related
• Interventions: Drug: Buscopan 20 MG/ML Injectable Solution; Drug: Placebo; Drug: Nacl 0.9%; Drug: Sodium bicarbonate

• Registration Number: NCT05719467
• Lead Sponsor: Oslo University Hospital

Brief Summary

Over the past years, the rates of labor induction have increased steadily, and at present more than one in four births occurs after induced labor in Norway. There is evidence that several groups of women benefit from labor induction, including those with preeclampsia (1), postdate pregnancy, diabetes, a large-for-gestational-age fetus, gestational diabetes, prelabor rupture of membranes at term, preterm prelabor rupture of membranes, twin pregnancy and intrahepatic cholestasis of pregnancy.

At the same time, induction of labor is an independent risk factor for adverse obstetric outcomes, including cesarean section, operative vaginal delivery, chorioamnionitis, labor dystocia, prolonged labor, uterine rupture, and neonatal pH \< 7.10. A recent Norwegian nationwide clinical practice pilot evaluation demonstrated that the rate of intervention was high, and that as many as 44% of women with labor induction experienced operative delivery.

Given that induction of labor is a common procedure (15 000 women per year in Norway) and increases risk of several major obstetric complications, interventions that may reduce operative births and facilitate safe deliveries are highly warranted.

Bicarbonate and butylscopolamine bromide have been used in smaller studies in order to shorten labor. The medications seem to be safe with a low frequency of adverse events.

The rationale of the present study is therefore to assess the efficacy of oral bicarbonate and intravenous butylscopolamine bromide on facilitating spontaneous (non-operative) delivery in pregnant female participants with induction of labor.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-12-18
• Study Start: 2023-01-03
• Study First Submitted QC: 2023-02-07
• Study First Posted: 2023-02-09
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-02
• Last Update Posted: 2024-04-04
• Primary Completion: 2025-01-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 3000

Inclusion Criteria

1. Participant must be between 18 and 50 years of age at the time of signing the informed consent.
2. Participants who are female, pregnant, nulliparous and at or above 37 weeks of gestation
3. Participants who fulfill hospital criteria for induction of labor, and where a decision to induce labor has been made
4. Participants carrying a fetus in vertex position
5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion Criteria

1. Multiple gestation
2. Elective cesarean section
3. Spontaneous start of labor
4. Known maternal intestinal stenosis, ileus or megacolon
5. Persisting maternal tachycardia (heart rate > 130 beats per minute) >30 minutes continuously.
6. Known maternal myasthenia gravis
7. Persisting fetal tachycardia (fetal heart rate baseline > 170 beats per minute) >30 minutes continuously.
8. Maternal hypersensitivity to any of the ingredients in IMP (butylscopolamine bromide, bicarbonate or sodium chloride)
9. Women with heart disease who are under surveillance with heart rate monitoring during labor
10. Known fetal heart disease or known fetal malformations in the gastrointestinal system
11. Untreated maternal glaucoma
12. Maternal electrolyte disturbance: severe hyponatremia, severe hypokalemia
13. Maternal moderate/severe kidney failure (stage III-V: glomerulus filtration rate <59 ml/minute/1.73m2 )
14. Maternal elevated serum creatinine (>90umol/L)
15. Maternal elevated Alanine Aminotransferase (ALAT) >100 U/L. Participation can still be considered for participants with ALAT >100 U/L if explained by obstetric cholestasis or HELLP syndrome.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Buscopan and placebo	Buscopan 20 MG/ML Injectable Solution	-
Placebo and placebo	Placebo	-
Placebo and bicarbonate	Nacl 0.9%	-
Buscopan and placebo	Placebo	-
Buscopan and bicarbonate	Buscopan 20 MG/ML Injectable Solution	-
Placebo and placebo	Nacl 0.9%	-
Buscopan and bicarbonate	Sodium bicarbonate	-
Placebo and bicarbonate	Sodium bicarbonate	-

Primary Outcome Measures

Name	Time	Method
Spontaneous vs operative birth	Through study completion, an average of one week	Number of participants with operative birth as compared to spontaneous birth

Trial Locations

Locations (5)

Akershus University Hospital; 🇳🇴 Lørenskog, Norway

Oslo University Hospital Ullevål; 🇳🇴 Oslo, Norway

The University Hospital of North Norway; 🇳🇴 Tromsø, Norway

Stavanger University Hospital; 🇳🇴 Stavanger, Norway

Oslo University Hospital Rikshospitalet; 🇳🇴 Oslo, Norway